

## Riverbend Medical Center Regional Infusion Center (RIC) 3377 Riverbend Drive Suite 502/510 Springfield, Oregon 97477 Phone 541-222-6280 Fax 541-349-8006

## MEPOLIZUMAB (Nucala) Injection (v. 05/21/2024)

Diagnos	sis/Indication (ICD-10):		
Medicatio	n:		
	Mepolizumab 100 mg subcutaneous every 4 weeks Mepolizumab 300 mg subcutaneous every 4 weeks		
Nursing co	ommunications:		
	Vital signs: Initial and prn Monitor patient for 30 minutes post-injection		
Emergeno	cy Medications:		
n	DiphenhydrAMINE (BENADRYL) 25 to 50 mg IV a		_
	ches, diaphoresis, fever, palpitations, chest discomfort	blood pressure changes (>/= 2	30 points in SBP), nausea, urticaria,
	pruritic).	± 0±+ 0r	
	Administer 25 mg IV once, if reaction does not resolve	m 3 mmutes may repeat 25 mg	g IV dose for a total of 50 mg and contact
<b>provi</b> en	ner.  MethylPREDNISolone sodium succinate (Solu-MI	EDDOI) 107 W	
sympt pressu	oms of mild to moderate drug reaction (flushing, dizzing changes (>/= 20 points in SBP), nausea, urticaria, nhydramine (Benadryl). Contact provider if given.	iness, headaches, diaphoresis, f	ever, palpitations, chest discomfort, blood
n	Epinephrine 0.3 mg IM once for anaphylaxis. If read	ction does not resolve in 3 minute	es may repeat 0.3 mg IM dose for a total of
0.6 mg	g. Avoid use of hand, foot, leg veins in elderly patient and		
n	Famotidine (PEPCID) 20 mg IV once as needed for infusi		
n	Emergency medications can be given IM if IV route unav	_	
		-	:
ight	Weight	Date:	Time: